-
Drug Discovery Needs Active Learning, Not Just Better Prediction
-
Better Assay Sequencing May Matter More Than Better Affinity Prediction
-
Why Benchmark Winners Often Make Poor Project Copilots
-
Cheap Experiments Are a Modelling Advantage
-
The Best Deployment Metric May Be Compounds Not Made
-
Medicinal Chemistry Is a Bandit Problem
-
The Project Is the Unit of Optimisation
-
The Future of Drug Discovery AI Is Retrieval as Much as Prediction
-
The Hardest Part of Molecular ML Is Target Definition
-
Drug Discovery Does Not Have an Intelligence Problem
-
Animal Testing Is Here to Stay
-
Design Without Routes Is Aimless
-
Patents as a Verifier
-
Rationality Rules?
-
Binding Affinity Is Not a Context-Free Label
-
Patent Data Is Not One Dataset. It Is Five.
-
Patent Data Is the Most Underused Asset in Small-Molecule AI
-
Taking the Queen and Losing the Game
-
What Exactly Is Your Drug Discovery Model Replacing?
-
Scaffold Splits Are Not the Gold Standard
-
Local Learning Is the Real Superpower in Drug Discovery AI
-
AI-Augmented Assay Cascades
-
Chemist Insight Is First-Class Data
-
Stop Collapsing Conformation Space
-
When Generation Becomes Cheap, Expertise Moves to Selection
-
Blaise Is Built for Saying No
-
Stop Using Eroom's Law Wrong
-
Why Federated Learning for ADME Is Doomed to Fail
-
Most ADME ML Models Are Confidently Wrong
-
Blaise AI Beta: Entity-Linked AI for Medicinal Chemistry
-
Beyond the Blockbuster: Is Biotech Entering Its Marvel Phase?
-
Blaise AI on Mobile: SAR in Your Pocket